UK 21: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 131785 |
SCHEMBL ID | 9768757 |
MeSH ID | M0209524 |
Synonym |
---|
134423-92-0 |
2',3',5'-tris-o-(n -(2-n-propyl-n-pentanoyl)glycyl)-5-fluorouridine |
glycine, n-(1-oxo-2-propylpentyl)-, triester with 5-fluorouridine |
uk 21 |
uk-21 |
[(2r,3r,4r,5r)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-bis[[2-(2-propylpentanoylamino)acetyl]oxy]oxolan-2-yl]methyl 2-(2-propylpentanoylamino)acetate |
SCHEMBL9768757 |
DTXSID20158693 |
2',3',5'-tris-o-[n-(2-n-propyl-n-pentanoyl)glycyl]-5-fluorouridine |
uk21 |
2',3',5'-tris-o-(n-(2-n-propyl-n-pentanoyl)glycyl)-5-fluorouridine |
Excerpt | Reference | Relevance |
---|---|---|
" However, the bioavailability of UK-21 given orally did not seem to be good." | ( Novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21: antitumor activity and effect on humoral immune response in mice. Kaku, Y; Kita, J; Koda, A; Maeda, D; Mori, H; Nagai, H; Nakayama, K, 1994) | 0.29 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.70) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |